42.49

0.57% +0.24

After Hours: 42.49

MoonLake Immunotherapeutics (MLTX)

Overview News Price History Option Chain Why MLTX Down? Discussions Forecast

MoonLake Immunotherapeutics stock is currently priced at $42.49, with a 24-hour trading volume of 222.43K. It has seen a +0.57% increased in the last 24 hours and a -15.16% declined in the past month. The chart indicates a potential bullish trend, as the stock is above the $42.04 pivot point. If it approaches the $42.87 resistance level, significant changes may occur.

Previous Close:

$42.25

Open:

$42.37

24h Volume:

222.43K

Market Cap:

$2.67B

Revenue:

Net Income/Loss:

$-36.01M

P/E Ratio:

-36.34

EPS:

-1.1692

Net Cash Flow:

$-42.78M

1W Performance:

+0.71%

1M Performance:

-15.16%

6M Performance:

-17.58%

1Y Performance:

+104.48%

1D Range:

$42.16

$43.05

52W Range:

$20.29

$64.98

MoonLake Immunotherapeutics Stock (MLTX) Company Profile

Name

MoonLake Immunotherapeutics

Sector

Healthcare (1191)

Industry

Biotechnology (688)

Phone

Address

Dorfstrasse 29, Zug

Employee

Twitter

Next Earnings Date

2024-03-20

Latest SEC Filings

MLTX's Discussions on Twitter

MoonLake Immunotherapeutics Stock (MLTX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Feb-15-24	Initiated	Wolfe Research	Outperform
Dec-08-23	Initiated	Citigroup	Buy
Nov-02-23	Initiated	Stifel	Buy
Sep-14-23	Downgrade	Bryan Garnier	Buy → Neutral
Aug-31-23	Initiated	Needham	Buy
Jun-15-23	Initiated	Barclays	Equal Weight
May-01-23	Initiated	Guggenheim	Buy
Mar-22-23	Initiated	Wedbush	Outperform
Mar-09-23	Initiated	BTIG Research	Buy
Feb-14-23	Initiated	Cantor Fitzgerald	Overweight
Feb-02-23	Initiated	Bryan Garnier	Buy
Nov-11-22	Initiated	Jefferies	Buy
Aug-25-22	Initiated	SVB Leerink	Outperform
Jul-21-22	Initiated	H.C. Wainwright	Buy
Jul-07-22	Initiated	Cowen	Outperform

View All

MoonLake Immunotherapeutics Stock (MLTX) Latest News

MoonLake announces significant improvements with Nanobody® sonelokimab over 24 weeks in active psoriatic arthritis (PsA) and other important updates at its R&D Day

GlobeNewswire Inc.

MoonLake Immunotherapeutics to present MIRA trial data of Nanobody® sonelokimab in hidradenitis suppurativa as a late breaker at the AAD Annual Meeting 2024

GlobeNewswire Inc.

Cooper Companies Reports Upbeat Results, Joins Dell, NetApp, Tidewater And Other Big Stocks Moving Higher On Friday

Benzinga

MoonLake Immunotherapeutics Announces Positive Feedback from both FDA and EMA on Regulatory Path for the Phase 3 Program of the Nanobody® sonelokimab (SLK) in Hidradenitis Suppurativa (HS)

GlobeNewswire Inc.

Is MoonLake Immunotherapeutics (MLTX) Stock a Solid Choice Right Now?

Zacks Investment Research

The best-performing stock of the year rose nearly 10-fold, while the 2nd-best averted disaster to surge 1,000% in a wild 2023

MarketWatch

MoonLake Immunotherapeutics Stock (MLTX) Financials Data

MoonLake Immunotherapeutics (MLTX) Net Income 2024

MLTX net income (TTM) was -$36.01 million for the quarter ending December 31, 2023, a +34.79% increase year-over-year.

MoonLake Immunotherapeutics (MLTX) Cash Flow 2024

MLTX recorded a free cash flow (TTM) of -$42.78 million for the quarter ending December 31, 2023, a +23.49% increase year-over-year.

MoonLake Immunotherapeutics (MLTX) Earnings per Share 2024

MLTX earnings per share (TTM) was -$0.74 for the quarter ending December 31, 2023, a +45.19% growth year-over-year.

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It is developing Sonelokimab, a novel investigational Nanobody therapy for the treatment of inflammation. The company is involved in conducting Phase II trials for hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis, or radiographic axial spondyloarthritis. MoonLake Immunotherapeutics was founded in 2021 and is headquartered in Zug, Switzerland.